AMPHのチャート
AMPHの企業情報
| symbol | AMPH |
|---|---|
| 会社名 | Amphastar Pharmaceuticals Inc (DE) （アムファスタ―・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アムファースター・ファーマシューティカルズ（Amphastar Pharmaceuticals Inc.）は専門的医薬品会社である。同社は汎用・注射・吸入製品の開発・製造・マーケティング・販売に従事する。同社は完成医薬品と医薬品原薬（API）製品の2つのセグメントを運営する。完成医薬品事業はエノキサパリン、コートロシン、アンファダーゼ、ナロキソン、リドカインゼリー、クリティカルおよびノンクリティカルケア薬を製造、販売、販売する。APIセグメントは、組換えヒトインスリンおよびブタインスリンを製造・販売する。 アムファスタ―・ファ―マシュ―ティカルズは、米国の製薬会社。技術的に困難なジェネリックと独自の注射用および吸入製品を開発、製造、マ―ケティング、販売する。同社の製品は、病院や緊急のケア臨床現場で使用され、グル―プ購入組織や卸売業者を通じて販売される。また、吸入製品は、医薬品の小売業者を通じて流通。 Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. |
| 本社所在地 | 11570 6th Street Rancho Cucamonga CA 91730 USA |
| 代表者氏名 | Mary Ziping Luo メアリー・ジッピン・ルオ |
| 代表者役職名 | Chief Operating Officer Chief Scientist and Chairman of the Board |
| 電話番号 | +1 909-980-9484 |
| 設立年月日 | 35096 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 1644人 |
| url | www.amphastar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/amph |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -1.46300 |
| 終値（lastsale） | 18.86 |
| 時価総額（marketcap） | 872396722.44 |
| 時価総額 | 時価総額（百万ドル） 879.79770 |
| 売上高 | 売上高（百万ドル） 247.75100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 881.49570 |
| 当期純利益 | 当期純利益（百万ドル） -14.79300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Amphastar Pharmaceuticals Inc revenues increased 6% to $129.4M. Net loss totaled $10M vs. income of $2.9M. Revenues reflect API segment increase from $2.2M to $13.1M France segment increase from $2.1M to $7.8M United States segment increase of 2% to $121.7M. Net loss reflects Research and development increase of 38% to $26.3M (expense) Other income (expense). |
AMPHのテクニカル分析
AMPHのニュース
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference - Stocks News Feed 2022/11/22 11:43:52 Stocks News Feed
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30th, 2022 at 11:00 am Eastern Time. […]
Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference 2022/11/22 11:08:00 Finanz Nachrichten
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, Sr. Vice President Regulatory Affairs and…
Amphastar: Growth Remains Intact (NASDAQ:AMPH) 2022/11/14 12:45:58 Seeking Alpha
Amphastar''s financial position is strong, offering significant flexibility. Read more here.
Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference 2022/11/10 21:08:00 Finanz Nachrichten
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, Executive V.P. of Corporate Admini…
Amphastar authorizes $50M buyback (NASDAQ:AMPH) 2022/11/08 07:16:42 Seeking Alpha
On November 3, 2022, Amphastar''s (AMPH) board authorized a $50 million increase to the company''s share buyback program, which is expected to continue for an indefinite period of…
Global Heparin Market to Touch a Revenue of USD 7938.6 Million by 2030; Rising Incidences of CVDs to Create Opportunities for Market Growth 2021/12/06 12:30:00 Intrado Digital Media
Key Companies Covered in the Heparin Market Research Report Are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and other key market players. Key Companies Covered in the Heparin Market Research Report Are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and other key market players.
State of Alaska Department of Revenue Has $512,000 Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) 2021/12/02 10:48:42 Transcript Daily
State of Alaska Department of Revenue raised its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,978 shares of the companys stock after buying an additional 1,600 shares during the []
Brokerages Expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Announce Quarterly Sales of $111.62 Million 2021/11/30 19:50:42 Transcript Daily
Equities research analysts expect that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will announce sales of $111.62 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amphastar Pharmaceuticals earnings, with estimates ranging from $109.00 million to $116.39 million. Amphastar Pharmaceuticals reported sales of $95.92 million during the same quarter last year, []
UBS Asset Management Americas Inc. Grows Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) 2021/11/25 10:56:41 Transcript Daily
UBS Asset Management Americas Inc. raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,811 shares of the companys stock after purchasing an additional 2,724 shares during the quarter. UBS Asset Management []
Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference 2021/11/22 11:08:00 FinanzNachrichten
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Commun
Recap: Amphastar Pharmaceuticals Q4 Earnings 2021/03/15 17:00:00 Benzinga
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share …
Amphastar Pharmaceuticals Is it time to Buy before this week’s earning report Stock market Insights & financial analysis 2021/03/15 16:47:00 Stock Market Daily
Amphastar Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Naloxone Market - Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc. 2021/03/09 13:56:31 OpenPR
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are
Low Molecular Weight Heparin Market – Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories 2021/03/02 07:53:20 OpenPR
Low Molecular Weight Heparin Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Sells $483,017.30 in Stock 2021/02/08 09:36:46 Watchlist News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Jack Y. Zhang sold 25,570 shares of the business’s stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $18.89, for a total value of $483,017.30. Following the completion of the transaction, the chief executive officer now owns 2,246,988 shares in the company, […]